Tactile Systems Technology (TCMD) Q2 2026 Earnings Call Transcript

Tactile Systems Technology (TCMD) reported Q2 revenue of $85.7M, up 9% YoY, with lymphedema revenue rising to $73.6M (+12% YoY) and gross margin expanding 180 bps to 76.3%. Adjusted EBITDA increased 49% YoY to $11.4M, and net income climbed to $7.8M ($0.34 diluted EPS) from $3.2M ($0.14) a year ago; management raised/updated FY2026 revenue guidance to $360M–$366M (+9% to +11% YoY) while maintaining FY2026 adjusted EBITDA of $49M–$51M. Offsetting headwinds include a temporary drag from an April 13, 2026 Medicare prior authorization requirement and a 7% YoY decline in airway clearance revenue due to distributor inventory management around next-gen AffloVest, though ordering is expected to normalize in Q4. The quarter also included $5.3M in share repurchases, and TCMD ended with $69.9M cash.

Analysis

The market should separate this into two businesses: one structurally improving, one temporarily noisy. The real earnings power is being pulled by the higher-margin lymphedema franchise, where reimbursement friction is still a headwind but not a demand problem; that usually means a near-term multiple reset is more about timing noise than fundamentals. If management is right that the Medicare workflow normalizes, the next 1-2 quarters can show operating leverage as the sales force/productivity investments were already made, which is why the margin profile matters more than the modest revenue guide trim.

The overhang is the airway-clearance channel, but the mechanism sounds like channel destocking around a product transition rather than end-demand destruction. That matters because destocking tends to create a sharper-than-expected sequential trough, then a mechanical rebound once inventories clear; the risk is that sell-side models underwrite a clean Q4 snapback that never fully arrives if DME partners stay conservative. The second-order winner is the company’s own mix: any reacceleration in the core lymphedema engine will make the 76%+ gross margin base look even more durable, which can support multiple expansion even before new products contribute.

Contrarian view: the consensus may be too focused on the latest revenue revision and not enough on the optionality embedded in access expansion. The new clinical data and diagnostic/reimbursement initiatives are not 2026 EPS drivers, but they can shift payer behavior over 6-18 months and widen the addressable pool enough to justify a higher steady-state growth rate. That said, if Q3 lymphedema growth decelerates materially or Medicare approval timelines worsen again, the thesis breaks quickly because the stock is not cheap enough to absorb both slower core growth and a delayed airway rebound.

Key Decisions for Investors

• Long TCMD on any 5-10% post-earnings pullback; target a 3-6 month re-rating if Q3 shows lymphedema acceleration and airway-clearance normalization. Risk/reward is favorable because gross margin expansion can keep EPS growing even with modest revenue noise.
• Pair trade: long TCMD / short a broader medtech ETF such as IHI for 1-3 months. The thesis is that TCMD’s margin leverage and reimbursement-normalization path should outperform a basket with slower, more mature growth profiles.
• Use a call spread in TCMD into the next 1-2 quarters if you want defined risk rather than equity exposure. Structure for a Q4 inventory rebound and any evidence that Medicare prior authorization is no longer depressing order flow; falsify if sequential revenue stalls again.
• Set a watch item rather than a buy on MyoSleeve and LymphaTech until 2027 reimbursement milestones are visible. These are option value, not base-case earnings drivers; if the market capitalizes them now, fade strength rather than chase it.